AVANT DIAGNOSTICS, INC. (OTCMKTS:AVDX) Files An 8-K Other EventsItem 8.01 Other Events.
On September 24, 2018, Avant Diagnostics, Inc. (the “Company”) issued a press release to provide comments regarding the trading halt of its common stock. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit No. | Description | |
| 99.1 | Press Release, dated September 24, 2018 |
Avant Diagnostics, Inc ExhibitEX-99.1 2 ex99-1.htm AVANT DIAGNOSTICS COMMENTS ON HALT OF TRADING OF COMMON STOCK Avant Diagnostics,…To view the full exhibit click here
About AVANT DIAGNOSTICS, INC. (OTCMKTS:AVDX)
Avant Diagnostics, Inc., formerly American Liberty Petroleum Corp., is a medical diagnostic technology company. The Company focuses on the commercialization of a series of microarray-based diagnostic tests that provide early detection of cancers, neurodegenerative diseases, and other chronic and severe disease states. The Company specializes in large panel biomarker tests. The Company’s lead product is OvaDx, a non-invasive proteomics diagnostic screening test for the early detection of ovarian cancer. The Company’s primary activities are preparing sample specimens in order for OvaDx to obtain the United States Food and Drug Administration (FDA) approval. The Company’s product, OvaDx, is a microarray-based test that measures the activation of the immune system in blood samples in response to early-stage ovarian tumor cell development. It identifies stage I, II, III and IV disease markers in patient samples.
